leadf
logo-loader
viewBiocept Inc

Biocept reaches deal to cover out-of-network patients for its liquid biopsy tests

Medical Cost Containment Professionals is a reference-based pricing insurance network that includes more than 150,000 providers in the US

People with glasses/goggles and lab coats gesturing to and looking at computer
Biocept’s Target Selector technology detects and isolates cancer biomarkers such as circulating tumor cells and cell-free circulating tumor DNA

Biocept Inc (NASDAQ:BIOC) has agreed to a managed care provider agreement with Medical Cost Containment Professionals LLC (MCCP) to process out-of-network insurance claims for its Target Selector liquid biopsy testing.

MCCP is a reference-based pricing insurance network that includes more than 150,000 providers in the US, the company said. 

"MCCP has a reputation for paying out-of-network claims correctly, in full and on time; and we are delighted to be working with them," Biocept Senior Director of Managed Care Strategies Dede Goehler said in a statement. "Under this new relationship, out-of-network claims for our Target Selector testing will be adjudicated by MCCP at pre-negotiated pricing in a timely manner, helping to accelerate collections while reducing the length of time receivables remain outstanding."

READ: Biocept makes available 10,000 nasopharyngeal specimen collection kits used in coronavirus testing

MCCP was founded with the goal of lowering healthcare costs in the US and claims its business model allows for negotiation of 80% of the claims it receives, regardless of amount.

"This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," Biocept CEO Michael Nall said. "MCCP's network includes 47 million covered lives, with some members covered by multiple plans.”

“We are working to enter into additional similar partnerships that help adjudicate out-of-network claims, as well as with managed care plans for in-network coverage for their members," he added. 

Biocept’s Target Selector technology detects and isolates cancer biomarkers such as circulating tumor cells and cell-free circulating tumor DNA. It offers the tests commercially to doctors, hospitals, clinics and researchers, with a focus on lung, breast, gastric, colorectal and prostate cancers — which represent 45% of all metastatic cancers — as well as melanoma.

The company says these simple blood tests can obtain the needed molecular information non-invasively and more rapidly than a tissue biopsy.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Biocept Inc

Price: 4.49 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $60.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Biocept receives CE-IVD Mark for Target Selector test kit...

Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE...

on 5/5/20

2 min read